Marcus Dijk - Mink Therapeutics Chief Officer

Mink Therapeutics Management Efficiency

The company has return on total asset (ROA) of (1.2036) % which means that it has lost $1.2036 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.3898) %, meaning that it created substantial loss on money invested by shareholders. Mink Therapeutics' management efficiency ratios could be used to measure how well Mink Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Mink Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 578.17 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.8 K). At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 7.3 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 5.4 M in 2025.

Similar Executives

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. Mink Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. Mink Therapeutics (INKT) is traded on NASDAQ Exchange in USA. It is located in 149 Fifth Avenue, New York, NY, United States, 10010 and employs 31 people. Mink Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Mink Therapeutics Leadership Team

Mink Stock Performance Indicators

Additional Tools for Mink Stock Analysis